-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Introducing a Therapeutic Option in Relapsed/Refractory AML/ALL

Sponsor: Syndax Pharmaceuticals
Program: Industry Theaters
Hematology Disease Topics & Pathways:
Diseases, Myeloid Malignancies
Sunday, December 8, 2024: 8:00 AM-9:00 AM
Room 5A (San Diego Convention Center)
Speaker:
Angela Smith, MD, MS, Syndax Pharmaceuticals
Disclosures:
No relevant conflicts of interest to declare.

This presentation is intended for U.S. based registered meeting attendees

For in-person participants only
See more of: Industry Theaters
<< Previous Session | Next Session >>